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Abstract: Abnormal activation of canonical Wnt signaling has been associated with various types of cancer. Inhibitory reagents 
targeting the Wnt signaling have great potential to inhibit the growth of relevant tumors. Here we generated a cell-based screening 
strategy for identification of antagonists of the Wnt/β-catenin signaling pathway. Stable expression wnt3a was generated in 
HEK293 cell line, which harbors dual-luciferase reporters. The Wnt signaling in the stably transfected cell line was proved to be 
very sensitive to (–)-epigallocatechin-3-gallate (EGCG) and lithium chloride (LiCl) treatment, respectively. Natural compounds 
were screened and a couple of novel inhibitory modulators of the Wnt signaling pathway were obtained. 
Keywords: Wnt signaling, natural compounds, dual-luciferase reporter, tumor
Introduction 
In the past several decades, the obvious importance of the 
cell signaling pathways as potential cancer therapeutic targets 
has stimulated researchers and pharmaceutical companies to 
develop numerous chemical inhibitors of these pathways like 
the Hedgehog and Notch signaling pathways1. Canonical 
Wnt/β-catenin pathway is essential for normal development 
and the maintenance of tissue stem cells2,3. This pathway can 
be activated by the binding of the Wnt ligands to its membrane 
receptor complex, resulting in the inhibition of the β-catenin 
destruction complex and subsequent trans-activation of β-
catenin target genes promoting proliferation2. Wnt/β-catenin 
pathway is frequently abnormal in many types of malignancies 
such as colon cancer4–6, liver cancer7, leukemia8,9, melanoma10, 
pancreatic cancer11, and breast cancer12. The activation state is 
due to mutations, such as oncogene β-catenin or the tumor 
suppressor gene APC and Axin2 in colon cancers, resulting in 
abrogated destruction complexes, consequently constitutive 
active and stabilized β-catenin proteins13. 
To explore the potential anti-tumor drug leads targeting the 
Wnt signaling pathway from the natural compounds, we  
generated a dual-luciferase reporter assay and utilized for 
screening the inhibitors of Wnt signaling pathway. Several 
inhibitory compounds were discovered and the structure-
activity relationship was analyzed. 
Results and Discussion 
Generation of wnt3a Stably Expressed Cell Line 
HEK293W. HEK293 cells were co-transfected with TopFlash, 
renilla reporters and wnt3a. For obtaining stable transfectants, 
several G418 and hygromycin B resistant clones were isolated. 
These G418 and hygromycin B resistant clones were verified 
by luciferase reporter assay. Figure 1 showed that 6 clones 
expressesed remarked TopFlash luciferase activity and no 
signal was detected in control HEK293 cells. Clone 6 showed 
 
Figure 1.  HEK293 cells were co-transfected with TopFlash, 
wnt3a and renilla plasmids. 6 clones were identified (G418 
and hygromycin B resistant) by reporter assay analysis. 
Figure 1 showed that 6 clones expressesed luciferase activity 
and no signal was detected in control HEK293 cells. Clone 6 
shown significantly high luciferase activity compared to other 
clones. 
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significantly high luciferase activity compared with others 
clones, and was named HEK293 Wnt3a-expressed (HEK293W). 
 
Wnt Signaling in HEK293W Cell Line was Sensitive to 
EGCG and LiCl Regulation. In order to test whether the Wnt 
signaling in HEK293W cell line was sensitive to be regulated, 
we treated the cells with (–)-epigallocatechin-3-gallate (EGCG) 
and lithium chloride (LiCl), a Wnt signaling inhibitor and  
agonist, respectively. EGCG inhibits the activity of Wnt/β-
catenin signaling14, whereas, LiCl inhibits GSK-3β and  
subsequently interferes the β-catenin degradation complex, 
leading to the accumulation of β-catenin in cytoplasm and 
nucleus. As shown in Figure 2A, EGCG inhibits the activity of 
Wnt/β-catenin signaling in a dose-dependent manner, and LiCl 
activated Wnt signaling in a dose- and time-dependent manner 
in HEK293W cells in Figure 2B. Furthermore, we tested 
whether tumor chemotherapeutic drugs such as Paclitaxel and 
Cisplatin (DDP) inhibited Wnt signaling in HEK293W cell 
line. The Figure 2C showed that neither of them showed  
obvious effects on the luciferase activity, suggesting the  
specific activation of Wnt signaling pathway in HEK293W 
cell line. 
To extend our studies to the expression of Wnt target genes 
which are known tobe regulated by Wnt/β-catenin signaling in 
mammalian cells, we monitored mRNA expression of Axin2, 
Cyclin D1 and protein expression of survivin, Cyclin D115,16. 
The Figures 2D–F showed that EGCG inhibited the expression 
of these target genes whereas LiCl increased the expression in 
HEK293W cell line. 
 
The Nuclear and Cytoplasmic β-Catenin were Increased 
in HEK293W Cells Compared with HEK293 Cells. Overall 
increase of the nuclear and cytoplasmic free β-catenin was 
further confirmed by immunofluorescence in HEK293W cells, 
using an anti-β-catenin antibody. The results revealed that the 
remaining of β-catenin was found to be concentrated in  
adherence junctions in HEK293 cells (Figure 3, red  
arrowheads). Compared with HEK293 cells, the active form of 
β-catenin was increased in the nucleus and free β-catenin was 
elevated in the cytoplasm in HEK293W cells. Taken together, 
our study suggests that HEK293W was expressed a robust  
β-catenin/TCF transcriptional activation which could be  
monitored easily by the TopFlash reporter. 
 
Figure 2.  HEK293W cell line was sensitive to EGCG and LiCl regulation of Wnt signaling pathway. (A) EGCG inhibited the 
activity of Wnt/β-catenin signaling in a dose-dependent manner. (B) LiCl activated Wnt signaling in a dose- and time-dependent 
manner. Triplicate experiments were done, and the results were expressed as mean ± SD (error bars). Significant inhibitions or 
activations (p < 0.05) were observed in HEK293W cells. TopFlash reporter gene activation is expressed in terms of relative light 
units (RLU) and normalized with renilla activity. (C) Paclitaxel (taxol) and Cisplatin (DDP) had no effects on luciferase activity in 
HEK293W cells. (D) Quantitative real-time RT-PCR showed that EGCG inhibited the target genes expression of Wnt signaling and 
(E) showed LiCl increased the target gene Axin2 expression in HEK293W cells. Triplicate experiments were done, and the results 
were expressed as mean ± SD (error bars). Statistical significance was determined by paired t test. *, P < 0.05; **, P < 0.01. 
Significant inhibitions or activations (p < 0.05) were observed in HEK293W cells. (F) Western blotting assay showed EGCG 
inhibited the expression of TCF/β-catenin target genes Cyclin D1 and Survivin in HEK293W cells, with β-actin as loading control. 
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Screening of Inhibitors Targeting the Canonical Wnt 
Signaling. To discover small molecular inhibitors targeting the 
canonical Wnt signaling, we employed reporter assays and 
screened compounds from a library of natural compounds, 
which are selected based on the structural diversity, stability, 
and molecular mass. The initial screening concentration was 
set from 10 μM and positive hits were considered when  
inhibition ratio is higher than 50% (red dotted line in Figure 4). 
About 2000 compounds were screened in the primary tests, 
more than 10 compounds exhibited inhibitory effects, and the 
positive ratio approximately 1%. In the following re-screening 
tests of the primary hits, the reporter cells were incubated with 
various concentrations of the compound to estimate the  
potential inhibitory effects with IC50. Among the primary hits, 
a series of hlsp derivatives exhibited obvious inhibitory activity
towards Wnt signaling pathway. In the secondary screening, 
compounds hlsp-2 and hlsp-19 exhibited significantly  
inhibitory effect in a dose dependent manner in HEK293W 
cells, and the IC50 value was 0.78 ± 0.18 μΜ and 0.33 ± 0.08 μM, respectively (Figure 5B–C). However, the analogue  
hlsp-1 showed no effect on Wnt signaling (Figure 5A). These  
compounds were isolated from the root bark of Meliaazedarach
and showed obvious cytotoxicity towards tumor cell lines in 
vitro17. Furthermore, we analyzed the structure-activity  
relationship among hlsp-2, hlsp-19 and hlsp-1 (Figures 5D–E). 
Base on compound hlsp-2 and hlsp-19 exhibited significantly 
inhibitory effect on Wnt signaling, which only were acetylated 
individually at C-7 or C-29, whereas hlsp-1 showed markedly 
decreased inhibitory activity on Wnt signaling, we proposed 
that existed deacetylation simultaneously at C-7 and C-29 may 
be responsible for the inhibitory effect on Wnt signaling. We 
will further explore the activity and the machenisms of these 
compounds with various Wnt pathway-dependent cancer cell 
lines. 
Conclusion 
Natural products have played a critical role in the field of 
cancer chemotherapy and numerous marketed drugs are of 
natural origin, either as derivatives or after modification18,19. 
However, the lack of biological activity and relevant 
pharmacological research limits their use as drugs for 
treatment disease. It remains a challenge to demonstrate the 
mechanism and the target of anti-tumor effect of natural 
compounds while the cytotoxic profiles can be tested easily. 
In the present study we set up a cell-based assay for  
identifying novel selective inhibitors targeting Wnt signaling 
pathway by using a Dual-Lucy Assay system20. This reporter 
gene system provides a simple and sensitive assay which can 
serve as an effective screening model to identify Wnt signaling 
inhibitors. Combining with the further activity and mechanism 
study with Wnt-dependant tumor cells, the potential of the 
inhibitors screened in this study as anti-tumor drug leads  
targeting the Wnt signaling pathway will be explored. 
 
Experimental Section 
Materials. HEK293 cell line was obtained from the  
American Type Culture Collection (ATCC) and cultured  
according to supplier’s instructions; Lipofectamine 2000  
(Invitrogen); Mouse monoclonal anti-β-catenin (BD); Mouse 
monoclonal anti-Cyclin D1, survivin and β-actin (Santa Cruz 
Biotechnology); Anti-mouse monoclonal IgG HRP conjugated 
secondary antibody (Santa Cruz Biotechnology); SuperSignal@
West Pico (Thermo scientific); TopFlash, Renilla reporters 
and wnt3a plasmids with selectable Neo or Hyg were kindly 
gifted by Dr. Mao (Kunming Institute of Zoology, CAS);  
Hygromycin B, G418 and EGCG were purchased from Sigma. 
The library of natural compounds was obtained from the State 
 
Figure 3.  Distribution of β-catenin in HEK293W and HEK293 cells. β-catenin (red arrowheads) was observed present in the nucleus 
in HEK293W cells whereas β-catenin was not detected in the nucleus and remaining β-catenin was concentrated in adherent 
junctions (red arrowheads) in HEK293 cells. 
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Key Laboratory of Phytochemistry and Plant Resources in 
West China. 
 
Cell Culture and Transfection. HEK293 cells were  
propagated in Dulbecco’s modified Eagle’s medium  
supplemented with 10% FBS, 100 μg/mL streptomycin and 
100 U/mL penicillin in a humidified atmosphere with 5% CO2. 
Stable cell line HEK293W was obtained by co-transfection of 
TopFlash and Renilla and the wnt3a into HEK293 cells using 
Lipofectamine 2000 reagent according to the manufacturer’s 
instructions (Invitrogen). After 24 h of transfection,  
hygromycin B and G418 were added, and the cells were  
selected for 14 days. The cell colonies were then detached and 
reseeded onto 6-well plate. Stable clones were selected for 
resistance to G418 and hygromycin B. Reporter gene assay 
was performed to monitor the success of stable transfection. 
 
TopFlash Reporter Assay. HEK293W cells were seeded in 
96 well plate containing 100 μL DMEM and 10% FBS. Drugs 
were added 12 h later and luciferase activities were measured 
24 h later, using the Dual-Lucy Assay Kit (Promega)  
according to the manufacturer’s protocol. Luminescence was 
measured in the Thermo Luminoskan Ascent. Analysis of  
inhibitors dose-response data and calculation of IC50 values 
were performed using GraphPad Prism (GraphPad Software). 
 
Real-Time RT-PCR. Total RNA was extracted from 
HEK293W cells using Trizol (Invitrogen). First strand cDNA 
was made using Superscript II reverse transcriptase  
(Invitrogen) with oligo dT. The Axin2 forward primer was 5'-
CTGGAGAGGGAGAAATGCGT-3' and the reverse primer 
was 5'-ATCTGCTGCTTCTTGATGCCA-3'. The Cyclin D1 
forward primer was 5'-AAGTGCGAGGAGGAGGTCTT-3' 
and the reverse primer was 5'-GGATGGAGTTGTCGGTGTAG
A-3'. The β-actin forward primer was 5'-CGCGAGAAGATGA
CCCAGAT-3' and the reverse primer was 5'-GATAGCACAG
CCTGGATAGCAAC-3'. Real-time RT-PCR experiments 
were performed in triplicate and PCR efficiency with given 
primers was between 95 and 105%. Melting curves were also 
performed for identification of primer-specific amplifications. 
The mRNA expression was normalized with β-actin. 
 
Figure 4.  Primary screening for identifying Wnt antagonists. The concentration of test compounds was set at 10 μM. The inhibition 
ratio of relative luciferase activity higher than 50% (red dotted line) relative to the negative control (DMSO) represents positive hits 
(by red signs). 
 
Figure 5.  Secondary screening tests of the primary hits. (A) 
The structures of hlsp-1, hlsp-2, and hlsp-19. (B) The IC50 
values of hlsp-1, hlsp-2 and hlsp-19 on Wnt signaling. (C–E) 
hlsp-1, hlsp-2 and hlsp-19 inhibited Wnt signaling in 
HEK293W cells, and the results were expressed as mean ± SD 
(error bars). 
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Immunocytochemistry. Cells were fixed with 4%  
paraformaldehyde and 0.1% Triton X-100 for 20 min at room 
temperature. The cells were blocked in 3% BSA for 30 min at 
room temperature and then were incubated with 1:500 dilution 
of appropriate primary antibody followed by incubation with 
1:1000 dilution FITC-conjugated secondary antibody. Cells 
were analyzed under a fluorescent microscope ECLIPSE Ti-S 
(Nikon Instech Co. Ltd., Japan). 
 
Western Blotting. The cell pellets were re-suspended in  
lysis buffer (50 mM Tris pH 7.6, 0.2 mM EDTA, 10 mM 
MgCl2, 0.2% Triton X-100, protease inhibitor cocktail) and 
homogenized. The homogenate was centrifuged at 12,000 g 
for 10 min at 4 °C. Protein samples were separated on 10% 
SDS-PAGE and were transferred to PVDF membranes. The 
membranes were incubated with mouse monoclonal antibody 
of Cyclin D1 or surviving at 1:1000 dilution followed by  
incubation with secondary antibody. Specific proteins were 
detected using Luminescent Image Analyzer LAS-4000mini 
system. 
 
Statistical Analysis. Statistical analysis was done using  
independent-sample T-test and the computer SPSS software. 
In all the assays, the probability value (p) of < 0.05 was  
considered statistically significant. 
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